Document 0834
 DOCN  M9440834
 TI    Factors associated with survival in human immunodeficiency
       virus-infected patients with very low CD4 counts.
 DT    9404
 AU    Colford JM Jr; Ngo L; Tager I; Center for AIDS Prevention Studies,
       University of California, San; Francisco.
 SO    Am J Epidemiol. 1994 Jan 15;139(2):206-18. Unique Identifier : AIDSLINE
       MED/94127459
 AB    The authors examined the survival experience of 289 human
       immunodeficiency virus (HIV)-infected men to identify factors
       independently associated with survival in patients with very low CD4
       counts (< or = 100/mm3). All subjects were HIV-infected men cared for at
       the San Francisco Veterans' Affairs Medical Center between January 1988
       and November 1991. Survival was measured from the date on which a
       patient was first known to have a CD4 count < or = 100/mm3 until death
       or censoring. Factors potentially associated with survival were examined
       initially using the product limit (Kaplan-Meier) method; a multivariate
       model of survival was constructed using a proportional hazards (Cox)
       regression. Four variables were identified as independently associated
       with survival (p < 0.05) in the Cox proportional hazards model: CD4
       count, hematocrit, azidothymidine use, and clinical stage (prior history
       of acquired immunodeficiency syndrome vs. no prior history). All 16
       possible combinations of these four (dichotomized) variables were
       examined; eight different patterns of survival were detected.
       Identification of survival patterns that can be described by data
       obtained as part of routine clinical care has implications for patient
       care, the design of clinical trials, the study of mechanisms of
       progression of HIV-related immunosuppression, and planning of health
       care resource needs for populations of patients with very low CD4
       counts.
 DE    Adult  Hematocrit  Human  HIV Infections/BLOOD/DRUG
       THERAPY/IMMUNOLOGY/*MORTALITY  *HIV-1  *Leukocyte Count  Male  Middle
       Age  Proportional Hazards Models  Support, U.S. Gov't, P.H.S.  Survival
       Rate  *T4 Lymphocytes  Zidovudine/THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).